Bayer is striving to improve people’s quality of life by diagnosing, preventing and treating a number of different conditions. In 2019, we invested a total of €5.3 billion in research and development globally. This figure represents a sound platform to introduce further innovative products in expanding life science markets
Bayer holds or aims to hold a worldwide leading position in its main therapeutic areas and our Pharmaceuticals portfolio focuses on:
General Medicine & Specialty Medicine - General Medicines consists of prescription products, especially for cardiology and women’s health, whilst Specialty Medicine covers the areas of neurology, oncology and ophthalmology. Bayer is a global leader in treatments for medical retina in ophthalmology and is expanding its research and development footprint in oncology.
Radiology - offers solutions to address different facets of patient care and workflow management in the radiology suite: contrast media and power injector systems, along with equipment service. In addition, the informatics platform, with protocol standardisation and easily accessible audit data, supports Radiology departments in facing challenges around contrast and radiation dose management.